GRF Grifols, S.A.

12.14USD11.07 EUR · BME-3.28%Mkt Cap: 8.26B USDP/E: 15.37

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates thr…

Institutional holders11 on file

Key Statistics

Company
Market Cap8.26B USD
Enterprise Value20.55B USD
Revenue (TTM)8.33B USD
Gross Profit3.14B USD
Net Income (TTM)440.91M USD
Revenue/Share12.24 USD
Last Price12.14 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees25.0K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - General
ISINES0171996087
Valuation
P/E (Trailing)15.37
P/E (Forward)10.12
PEG0.24
EV/EBITDA10.79
EV/Revenue2.47
P/S0.99
P/B1.30
EPS (TTM)0.79 USD
EPS (Forward)1.20 USD
52W Range
9.24880% of range12.87
52W High12.87 USD
52W Low9.248 USD
Profitability
Gross Margin38.00%
Oper. Margin18.85%
EBITDA Margin22.85%
Profit Margin5.34%
ROE7.63%
ROA2.04%
ROIC6.22%
ROCE7.07%
Growth
Revenue Growth9.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.15B USD
CapEx (TTM)463.95M USD
FCF Margin2.56%
FCF Yield2.58%
Net Debt9.60B USD
Net Debt/EBITDA5.04
Net Debt/FCF45.02
Balance Sheet
Debt/Equity1.81
Current Ratio2.33
Quick Ratio0.68
Book Value/Sh9.33 USD
Cash/Share0.78 USD
Dividends
Fwd Div Rate0.09 USD
Trail. Div Rate0.00 USD
Div. Yield0.72%
5Y Avg Yield1.33%
Payout Ratio11.57%
Ex-Div DateDec 2, 2026
Pay Date—
Splits
Last Split2:1
Split DateJan 4, 2016
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.73 USD
Upside (mean)+37.8%
Target Range9.871 USD – 25.99 USD
9.871+37.8% to mean25.99
# Analysts11
Ownership
Shares Out.422.36M
Float418.22M
Insiders31.19%
Institutions41.36%
Technical
SMA 5011.29 (+7.6%)
SMA 20010.68 (+13.7%)
Beta1.13
S&P 52W Chg12.00%
Avg Vol (30d)1.30M
Avg Vol (10d)1.80M
Technical Indicators
RSI (14)53.4
MACD0.3342
MACD Signal0.3753
MACD Hist.-0.0411
BB Upper13.11 USD
BB Middle12.24 USD
BB Lower11.37 USD
BB Width14.25%
ATR (14)0.2763 USD
Vol Ratio (20d)1.00x

About Grifols (BME: GRF)

›

Grifols (BME: GRF) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 25,000 employees.

The shares were at 11.07 EUR on 19 November 2026, up 9.1% over 52 weeks. Its 52-week range is 8.432 EUR to 11.73 EUR: the price is 5.6% below the high and 31.3% above the low.

At a market capitalisation of 7.53B EUR, it trades at 15.4 times trailing earnings and 10.1 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 41% for GRF. It pays a dividend yielding 0.72% (it pays out 12% of its earnings), against a median of 2.43% among the dividend payers in that peer group.

Grifols reports return on equity of 7.6%, an operating margin of 18.9% and revenue up 9.4% year over year.

Its debt exceeds its cash by 8.75B EUR, a debt-to-equity ratio of 1.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 15.25 EUR is 37.8% above the current price. The next earnings report is expected on 25 February 2027.